For a patient with hemoglobin 8 g/dL, how many grams of elemental iron should be administered intravenously and what dosing regimen should be used?

Intravenous Iron Dosing for Hemoglobin 8 g/dL

For a patient with hemoglobin 8 g/dL, administer 1000-1500 mg of elemental iron intravenously, preferably as ferric derisomaltose (FDI) 1000 mg single infusion or ferric carboxymaltose (FCM) 1000 mg, with the expectation of a 1-2 g/dL hemoglobin rise within 4-8 weeks 1.

Dose Calculation and Formulation Selection

The total iron deficit can be calculated using the formula: 3.4 × (target Hb - current Hb) × 65 × body weight/100 + 500 mg 2. For a 70 kg patient with Hb 8 g/dL targeting 12 g/dL, this equals approximately 1100 mg elemental iron.

Preferred IV Iron Formulations

First-line choice: Ferric derisomaltose (FDI)

• FDA-approved for total dose infusion up to 1500 mg single dose or 20 mg/kg (not exceeding 1500 mg)
• Dilute 1000 mg in 100 mL normal saline, infuse over 15-30 minutes
• Only formulation with mortality benefit in heart failure patients 1

Alternative: Ferric carboxymaltose (FCM)

• 1000 mg single infusion (standard in Europe/Asia)
• In US: 750 mg vials, typically given as two doses 1 week apart (1500 mg total)
• Dilute in 100 mL normal saline, infuse over 20-30 minutes
• Critical caveat: Avoid FCM for repeat infusions due to treatment-emergent hypophosphatemia risk 1

Iron sucrose (if above unavailable)

• Requires multiple smaller doses due to safety profile
• 200 mg infusions on 5 occasions over 14 days (total 1000 mg) for non-dialysis patients 3
• Less convenient but well-established safety record

Administration Protocol

1. Pre-infusion: Ensure resuscitation equipment available; observe for hypersensitivity reactions
2. During infusion: Monitor vital signs, watch for acute infusion reactions (flushing, chest discomfort, hypotension)
3. Post-infusion: Observe patient for 30 minutes after completion

Expected Response and Monitoring

Hemoglobin should increase by 1-2 g/dL within 4-8 weeks 1. Check CBC and iron parameters (ferritin, transferrin saturation) at 4-8 weeks post-infusion—not before 4 weeks, as circulating iron interferes with assays 1.

Target parameters:

• Ferritin ≥50 ng/mL (without inflammation)
• Transferrin saturation ≥20%
• Hemoglobin ≥12 g/dL

Critical Clinical Considerations

Identify and address the underlying cause before or concurrent with iron replacement:

• GI blood loss (most common in adults)
• Heavy menstrual bleeding
• Malabsorption (celiac disease, bariatric surgery, inflammatory bowel disease)
• Chronic kidney disease
• Heart failure

For ongoing losses, a single infusion will not suffice—repeat dosing every 3-4 months may be necessary depending on blood loss rate 1.

In specific populations:

• Pregnancy: The formula-based approach works well; IV iron shows superior efficacy to oral with Hb rising faster 4
• CKD patients: May require maintenance dosing; hemodialysis patients typically need 100 mg every dialysis session initially 3
• Heart failure: IV iron improves outcomes even with functional iron deficiency (ferritin <100 ng/mL or TSAT <20%) 5
• IBD: IV iron preferred when Hb <10 g/dL due to impaired oral absorption 5

Common Pitfalls to Avoid

1. Don't use oral iron as primary therapy at Hb 8 g/dL—it's too slow and poorly tolerated
2. Don't check iron studies within 4 weeks of IV infusion—results will be falsely elevated
3. Don't give FCM repeatedly if patient needs ongoing iron replacement—switch to FDI or iron sucrose to avoid hypophosphatemia
4. Don't assume anemia is solely iron deficiency—verify with ferritin <100 ng/mL and/or TSAT <20% before treating

The 1000-1500 mg total dose approach provides rapid, effective correction of iron deficiency anemia with minimal infusion visits, directly addressing both the hemoglobin deficit and depleted iron stores 1, 6.